Genetic testing for embryo selection in women undergoing IVF
GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial
This study is testing if using genetic testing to choose the best embryo for transfer can help women aged 35 to 40 have better pregnancy outcomes during IVF compared to standard methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 35 Years to 40 Years |
| Sex | Female |
| Sponsor | Genomic Prediction Inc. Industry-sponsored |
| Locations | 1 site (Waltham, Massachusetts) |
| Trial ID | NCT06141135 on ClinicalTrials.gov |
What this trial studies
The GETSET trial is a randomized clinical trial aimed at evaluating the outcomes of preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer among women aged 35 to 40. A total of 240 participants will be recruited and divided into two groups: one receiving standard embryo transfer and the other undergoing genetic testing to select the best quality euploid blastocyst for transfer. The trial will assess the effectiveness of this genetic testing approach in improving pregnancy outcomes compared to traditional methods.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 35 to 40 who are undergoing IVF and have at least one evaluable blastocyst.
Not a fit: Patients who may not benefit include those using donor oocytes, gestational carriers, or those with a history of recurrent pregnancy loss or implantation failure.
Why it matters
Potential benefit: If successful, this study could enhance the chances of successful pregnancies for women undergoing IVF by ensuring the transfer of genetically healthy embryos.
How similar studies have performed: Other studies have shown promising results with preimplantation genetic testing approaches, indicating potential benefits in embryo selection.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI (recommended) or ---Traditional IVF * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols Exclusion Criteria: * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers * Preimplantation genetic testing for monogenic/single gene disorders (PGT-M) * Translocation carriers
Where this trial is running
Waltham, Massachusetts
- Boston IVF — Waltham, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Nathan Treff, PhD — Genomic Prediction Clinical Labortory
- Study coordinator: Talia Metzgar
- Email: talia@genomicprediction.com
- Phone: (973) 529- 4223
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.